Nonlinear metrology with a quantum interface

We describe nonlinear quantum atom-light interfaces and nonlinear quantum metrology in the collective continuous variable formalism. We develop a nonlinear effective Hamiltonian in terms of spin and polarization collective variables and show that model Hamiltonians of interest for nonlinear quantum metrology can be produced in $^{87}$Rb ensembles. With these Hamiltonians, metrologically relevant atomic properties, e.g. the collective spin, can be measured better than the "Heisenberg limit" $\propto 1/N$. In contrast to other proposed nonlinear metrology systems, the atom-light interface allows both linear and non-linear estimation of the same atomic quantities.Comment: 8 pages, 1 figure

The Distribution of Nearby Stars in Velocity Space Inferred from Hipparcos Data

(abridged) The velocity distribution f(v) of nearby stars is estimated, via a maximum- likelihood algorithm, from the positions and tangential velocities of a kinematically unbiased sample of 14369 stars observed by the HIPPARCOS satellite. f(v) shows rich structure in the radial and azimuthal motions, v_R and v_phi, but not in the vertical velocity, v_z: there are four prominent and many smaller maxima, many of which correspond to well known moving groups. While samples of early-type stars are dominated by these maxima, also up to 25% of red main-sequence stars are associated with them. These moving groups are responsible for the vertex deviation measured even for samples of late-type stars; they appear more frequently for ever redder samples; and as a whole they follow an asymmetric-drift relation, in the sense that those only present in red samples predominantly have large |v_R| and lag in v_phi w.r.t. the local standard of rest (LSR). The question arise, how these old moving groups got on their eccentric orbits. A plausible mechanism, known from solar system dynamics, which is able to manage a shift in orbit space involves locking into an orbital resonance. Apart from these moving groups, there is a smooth background distribution, akin to Schwarzschild's ellipsoidal model, with axis ratio of about 1:0.6:0.35 in v_R, v_phi, and v_z. The contours are aligned with the $v_r$ direction, but not w.r.t. the v_phi and v_z axes: the mean v_z increases for stars rotating faster than the LSR. This effect can be explained by the stellar warp of the Galactic disk. If this explanation is correct, the warp's inner edge must not be within the solar circle, while its pattern rotates with frequency of about 13 km/s/kpc or more retrograde w.r.t. the stellar orbits.Comment: 16 pages LaTeX (aas2pp4.sty), 6 figures, accepted by A

Multiple Stellar Populations in the Globular Cluster omega Centauri as Tracers of a Merger Event

The discovery of the Sagittarius dwarf galaxy, which is being tidally disrupted by and merging with the Milky Way, supports the view that the halo of the Galaxy has been built up at least partially by the accretion of similar dwarf systems. The Sagittarius dwarf contains several distinct populations of stars, and includes M54 as its nucleus, which is the second most massive globular cluster associated with the Milky Way. The most massive globular cluster is omega Centauri, and here we report that omega Centauri also has several distinct stellar populations, as traced by red-giant-branch stars. The most metal-rich red-giant-branch stars are about 2 Gyr younger than the dominant metal-poor component, indicating that omega Centauri was enriched over this timescale. The presence of more than one epoch of star formation in a globular cluster is quite surprising, and suggests that omega Centauri was once part of a more massive system that merged with the Milky Way, as the Sagittarius dwarf galaxy is in the process of doing now. Mergers probably were much more frequent in the early history of the Galaxy and omega Centauri appears to be a relict of this era.Comment: 7 pages, 3 figures, Latex+nature.sty (included), To appear in November 4th issue of Natur

OBTAINING THE SENSED TEMPERATURES FROM A DETAILED MODEL OF A WELDED THERMOCOUPLE

ABSTRACT When imbedded in dissimilar materials subject to large temperature gradients, thermocouples are known to yield erroneous (bias) temperature measurements. It has been established that the bias error may be accounted for with an appropriate computational model and the measured temperatures may be corrected with an appropriate kernel function. In this work, a thermocouple with a welded bead is considered. Early two-dimensional models considered the thermocouple to be a single wire with effective thermal properties. The model in the current investigation is threedimensional and represents the sensor as two wires, each with unique thermal properties. The welded bead is represented as a separate entity with properties distinct from those of the wires. The problem of determining what location in the threedimensional model corresponds to the measured temperature is considered. Earlier models have considered the sensed temperature to be the temperature at the tip of the twodimensional thermocouple or, in three-dimensional models, the temperature at the center of the volume of the welded bead. In the current work, a theory is set forth for identifying the location at which the temperature is sensed by a thermocouple. This theory is in line with traditional thermoelectric theory and is supported with experimental evaluation with thermal imaging as well as examination of thermocouples by scanning electron microscopy and energy dispersive X-ray analysis. The significance of accurate modeling of the sensed temperatures is demonstrated with a numerical experiment

Perspective: Quantum Hamiltonians for optical interactions

The multipolar Hamiltonian of quantum electrodynamics is extensively employed in chemical and optical physics to treat rigorously the interaction of electromagnetic fields with matter. It is also widely used to evaluate intermolecular interactions. The multipolar version of the Hamiltonian is commonly obtained by carrying out a unitary transformation of the Coulomb gauge Hamiltonian that goes by the name of Power-Zienau-Woolley (PZW). Not only does the formulation provide excellent agreement with experiment, and versatility in its predictive ability, but also superior physical insight. Recently, the foundations and validity of the PZW Hamiltonian have been questioned, raising a concern over issues of gauge transformation and invariance, and whether observable quantities obtained from unitarily equivalent Hamiltonians are identical. Here, an in-depth analysis of theoretical foundations clarifies the issues and enables misconceptions to be identified. Claims of non-physicality are refuted: the PZW transformation and ensuing Hamiltonian are shown to rest on solid physical principles and secure theoretical ground

Longitudinal Analysis of Quality of Life, Clinical, Radiographic, Echocardiographic, and Laboratory Variables in Dogs with Preclinical Myxomatous Mitral Valve Disease Receiving Pimobendan or Placebo: The EPIC Study

Background: Changes in clinical variables associated with the administration of pimobendan to dogs with preclinical myxomatous mitral valve disease (MMVD) and cardiomegaly have not been described. Objectives: To investigate the effect of pimobendan on clinical variables and the relationship between a change in heart size and the time to congestive heart failure (CHF) or cardiac-related death (CRD) in dogs with MMVD and cardiomegaly. To determine whether pimobendan-treated dogs differ from dogs receiving placebo at onset of CHF. Animals: Three hundred and fifty-four dogs with MMVD and cardiomegaly. Materials and Methods: Prospective, blinded study with dogs randomized (ratio 1:1) to pimobendan (0.4-0.6 mg/kg/d) or placebo. Clinical, laboratory, and heart-size variables in both groups were measured and compared at different time points (day 35 and onset of CHF) and over the study duration. Relationships between short-term changes in echocardiographic variables and time to CHF or CRD were explored. Results: At day 35, heart size had reduced in the pimobendan group:median change in (Delta) LVIDDN -0.06 (IQR:-0.15 to + 0.02), P < 0.0001, and LA:Ao -0.08 (IQR:-0.23 to + 0.03), P < 0.0001. Reduction in heart size was associated with increased time to CHF or CRD. Hazard ratio for a 0.1 increase in Delta LVIDDN was 1.26, P = 0.0003. Hazard ratio for a 0.1 increase in Delta LA:Ao was 1.14, P = 0.0002. At onset of CHF, groups were similar. Conclusions and Clinical Importance: Pimobendan treatment reduces heart size. Reduced heart size is associated with improved outcome. At the onset of CHF, dogs treated with pimobendan were indistinguishable from those receiving placebo

Galactic Kinematics Towards the South Galactic Pole. First Results from the Yale-San Juan Southern Proper-Motion Program

The predictions from a Galactic Structure and Kinematic model code are compared to the color counts and absolute proper-motions derived from the Southern Proper-Motion survey covering more than 700 $\deg^2$ toward the South Galactic Pole in the range $9 < B_{\rm J} \le 19$. The theoretical assumptions and associated computational procedures, the geometry for the kinematic model, and the adopted parameters are presented in detail and compared to other Galactic Kinematic models of its kind. The data to which the model is compared consists of more than 30,000 randomly selected stars, and it is best fit by models with a solar peculiar motion of +5 km s$^{-1}$ in the V-component (pointing in the direction of Galactic rotation), a large LSR speed of 270 km s$^{-1}$, and a (disk) velocity ellipsoid that always points towards the Galactic center. The absolute proper-motions in the U-component indicate a solar peculiar motion of $11.0 \pm 1.5$ km s$^{-1}$, with no need for a local expansion or contraction term. The fainter absolute motions show an indication that the thick-disk must exhibit a rather steep velocity gradient of about -36 km s$^{-1}$ kpc$^{-1}$ with respect to the LSR. We are not able to set constraints on the overall rotation for the halo, nor on the thick-disk or halo velocity dispersions. Some substructure in the U & V proper-motions could be present in the brighter bins $10 < B_{\rm J} < 13$, and it might be indicative of (disk) moving groups.Comment: 24 double-column pages, 12 tables, AAS Latex macros v4.0, 19 B&W figures, 1 color figure. Accepted for publication on The Astronomical Journa

Effect of Pimobendan in Dogs with Preclinical Myxomatous Mitral Valve Disease and Cardiomegaly: The EPIC Study - A Randomized Clinical Trial

Background: Pimobendan is effective in treatment of dogs with congestive heart failure (CHF) secondary to myxomatous mitral valve disease (MMVD). Its effect on dogs before the onset of CHF is unknown. Hypothesis/Objectives: Administration of pimobendan (0.4-0.6 mg/kg/d in divided doses) to dogs with increased heart size secondary to preclinical MMVD, not receiving other cardiovascular medications, will delay the onset of signs of CHF, cardiac-related death, or euthanasia. Animals: 360 client-owned dogs with MMVD with left atrial-to-aortic ratio >= 1.6, normalized left ventricular internal diameter in diastole >= 1.7, and vertebral heart sum >10.5. Methods: Prospective, randomized, placebo-controlled, blinded, multicenter clinical trial. Primary outcome variable was time to a composite of the onset of CHF, cardiac-related death, or euthanasia. Results: Median time to primary endpoint was 1228 days (95% CI: 856-NA) in the pimobendan group and 766 days (95% CI: 667-875) in the placebo group (P = .0038). Hazard ratio for the pimobendan group was 0.64 (95% CI: 0.47-0.87) compared with the placebo group. The benefit persisted after adjustment for other variables. Adverse events were not different between treatment groups. Dogs in the pimobendan group lived longer (median survival time was 1059 days (95% CI: 952-NA) in the pimobendan group and 902 days (95% CI: 747-1061) in the placebo group) (P = .012). Conclusions and Clinical Importance: Administration of pimobendan to dogs with MMVD and echocardiographic and radiographic evidence of cardiomegaly results in prolongation of preclinical period and is safe and well tolerated. Prolongation of preclinical period by approximately 15 months represents substantial clinical benefit